Showing 2791-2800 of 5554 results for "".
- Good Deal: DS Healthcare Acquires Radiancy, Neovahttps://practicaldermatology.com/news/good-deal-ds-healthcare-acquires-radiancy-neova/2458692/DS Healthcare Group, Inc. will acquire Radiancy, Inc., and Neova® from PhotoMedex, Inc. The board of directors of both companies have voted unanimously in favor o
- Sweet Acne Cure: Kanuka Honey from New Zealand May Eradicate Acnehttps://practicaldermatology.com/news/sweet-acne-cure-kanuka-honey-from-new-zealand-may-eradicate-acne/2458693/Kanuka honey may help out the brakes on acne, new research suggests. In the study of Honevo®, developed by New Zealand pharmaceutical company HoneyLab, twice as many participants had an imp
- Dr. Bruce Strober Appointed Chair of Dermatology at UConn Healthhttps://practicaldermatology.com/news/dr-bruce-strober-appointed-chair-of-dermatology-at-uconn-health/2458694/Bruce E. Strober, MD, PhD has been appointed chair of the Department of Dermatology at UConn Health and professor of dermatology at UConn School of Medicine. Dr. Strober has served as the interim chair of the Department of Dermatology since 2015 and vice chair since joining UConn Health in 2011.
- Sturge-Weber Foundation to Host Dermatology Roundtablehttps://practicaldermatology.com/news/sturge-weber-foundation-to-host-dermatology-roundtable/2458697/The Sturge-Weber Foundation (SWF) is holding a Dermatology Discussion Roundtable meeting on March 5, 2016, at the Marriott Marquis in Washington, DC. Attendees of the American Academy of Dermatology (AAD) conference are invited to attend this breakfast meeting from 7:30 a.m. to 9:30 a.m. in the J
- Hidradenitis Suppurativa Ups Risk of Adverse CV Eventshttps://practicaldermatology.com/news/hidradenitis-suppurativa-ups-risk-of-adverse-cv-events/2458696/Hidradenitis suppurativa (HS) may increase risk for adverse cardiovascular outcomes, a new study suggests. HS has been associated with cardiovascular risk factors, such as smoking and obesity, but the risk of cardiovascular disease in patients with HS was unknown. The new study
- Cipher's Sitavig Accepted for Review by Health Canadahttps://practicaldermatology.com/news/ciphers-sitavig-accepted-for-review-by-health-canada/2458701/Cipher Pharmaceuticals Inc.’s New Drug Submission for Sitavig has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis in adults. In the United States, Sitavig® is approve
- Hilary Baldwin, MD, Named Medical Director of ATRChttps://practicaldermatology.com/news/hilary-baldwin-md-named-medical-director-of-atrc/2458710/The newly opened Acne Treatment and Research Center (ATRC) in Morristown, NJ, has tapped Hilary Baldwin, MD, to serve as its medical director. Dr. Baldwin received her BA and MA in biology from Boston Uni
- Bristol-Myers Squibb Foundation Awards 8 Grants to Make Skin and Lung Cancer Screening More Accessible in High-Risk U.S. Communitieshttps://practicaldermatology.com/news/bristol-myers-squibb-foundation-awards-8-grants-to-make-skin-and-lung-cancer-screening-more-accessible-in-high-risk-us-communities/2458721/Bristol-Myers Squibb Foundation awarded eight grants totaling nearly $11.5 million to help make skin and lung cancer screening programs, care and patient support more accessible to underserved populations. The grants we
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Educationhttps://practicaldermatology.com/news/novartis-teams-with-pro-football-hall-of-famer-troy-aikman-on-melanoma-education/2458727/Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the different mutations of melanoma. Campaign partners are asking patients and supporters to show th